From One Patient to Many: A Practical Guide to Building a Personalized Medicine Biotech (Lessons from Mila’s Story)

Overview

Julia Vitarello’s journey began when her daughter Mila received a single-patient, or n‑of‑1, therapy designed specifically for her rare genetic mutation. That success sparked a vision: to scale such bespoke medicines from one child to thousands. Vitarello’s first venture, EveryONE Medicines, aimed to do exactly that but eventually folded—partly because the FDA’s guidance for individualized therapies was still too tentative to satisfy investors. Now she is launching a new biotech, again seeking to turn personalized genetic treatments into a scalable reality. This guide distills the key steps, challenges, and lessons from her experience into a blueprint for anyone—scientist, entrepreneur, or advocate—looking to build a company that delivers truly individualized medicines at scale.

Prerequisites

Before diving into the step‑by‑step process, ensure you have:

• Scientific expertise – deep understanding of gene editing, antisense oligonucleotides, or other customizable modalities.
• Regulatory knowledge – familiarity with FDA’s n‑of‑1 drafts and expanded access pathways.
• Financial resources – initial capital for preclinical work and a network of investors willing to accept longer timelines.
• Patient‑centered mindset – willingness to collaborate closely with families and rare‑disease foundations.

Step‑by‑Step Guide

Step 1: Understand the N‑of‑1 Landscape

Start by mapping the current ecosystem. Vitarello’s experience with Mila showed that a single customized therapy can be life‑changing, but scaling requires a platform that can design, test, and manufacture one‑off molecules rapidly. Research the latest regulatory frameworks, such as the FDA’s 2023 draft guidance on individualized antisense oligonucleotides, and study companies like n-Lorem and IONIS that already run subsidized programs. Knowledge of the reimbursement and ethical landscapes is equally critical—each drug is unique, so traditional pricing models fail.

Step 2: Build a Scientific Foundation

Your technology platform must enable quick turnaround from mutation identification to drug candidate. Key components include:

• Rapid sequencing and variant interpretation – use whole‑genome sequencing and AI‑based tools to identify disease‑causing mutations.
• Modular drug design – for example, an antisense oligonucleotide (ASO) library where each sequence can be synthesized in weeks.
• High‑throughput screening – automated systems to test candidate molecules on patient‑derived cells.
• GMP manufacturing pipeline – ability to produce small batches (often milligrams) under sterile conditions.

A practical code‑like workflow: sequence_input → mutation_map → ASO_design → synthesis → QC → in vitro test → release. Each step must be documented for regulatory filing.

Step 3: Navigate Regulatory Pathways

The FDA does not have a specific approval pathway for n‑of‑1 therapies, but it has issued draft guidances. For each patient, you may need to submit:

1. An Investigational New Drug (IND) application – often streamlined for single‑patient studies.
2. An expanded access protocol – if the patient cannot wait for full IND approval.
3. Individual patient consent and Institutional Review Board (IRB) approval.

Vitarello’s EveryONE Medicines found that the 2022 draft guidance was insufficiently concrete for investors. Ensure your regulatory team proactively engages the FDA in pre‑IND meetings and advocates for clearer frameworks.

Step 4: Secure Funding and Investor Alignment

Traditional biotech VCs expect blockbuster returns. N‑of‑1 companies, by contrast, treat each drug as a loss leader. To attract capital:

• Pitch the platform, not the drug – emphasize the reusable technology that can address many mutations.
• Seek non‑dilutive funding – grants from the NIH, Cures Within Reach, and rare‑disease foundations.
• Build a social impact narrative – connect with impact investors who accept lower financial returns.
• Structure milestone payments – e.g., get paid per successful drug design, with fees sliding on family income.

EveryONE folded because its investors were not comfortable with the regulatory uncertainty. Clearly outline risks and your mitigation plan in the pitch deck.

Step 5: Develop a Scalable Manufacturing and Clinical Platform

To move from one patient to many, you need standardized operating procedures for every step – from mutation identification to drug release. Consider a digital platform that manages patient data, drug design history, and clinical outcomes. For manufacturing, partner with contract development and manufacturing organizations (CDMOs) that specialize in small‑batch ASOs or gene‑editing vectors. Automate as much as possible: Vitarello’s new company is exploring AI‑based sequence optimization and robotic synthesis to reduce per‑patient costs.

Step 6: Establish Patient and Advocacy Partnerships

Families like Mila’s are the heart of this model. Engage patient advocacy groups early—they can help identify mutation carriers, fund preclinical studies, and lobby for regulatory change. Create a transparent enrollment process, share data with the community, and offer compassionate use for patients who don’t qualify for trials. Vitarello’s success with Mila came from her relentless advocacy; your business model should make that advocacy a core feature, not an afterthought.

Common Mistakes

Mistake 1: Overreliance on Incomplete Regulatory Guidance

EveryONE Medicines assumed that the FDA’s 2022 draft guidance would soon solidify into a clear pathway. When it didn’t, investors backed out. Mitigation: invest in a regulatory team that pushes for concrete agency feedback through pilot programs and advisory meetings. Never base your entire timeline on a draft.

Mistake 2: Misaligned Investor Expectations

Many VCs expect a traditional drug development timeline (5‑7 years to approval). N‑of‑1 therapies are faster per drug, but each drug serves only one patient, limiting revenue. Solution: educate investors on the “platform royalty” model where the same technology is reused across hundreds of mutations. Show that cumulative revenue can rival a blockbuster if scaled to thousands of patients.

Mistake 3: Insufficient Scalability Planning

It’s tempting to focus on one miraculous case, but a sustainable company must design for volume from day one. Vitarello’s new venture is embedding scalability into every decision: modular labs, cloud‑based data management, and pre‑negotiated CDMO contracts. Without this, you will burn cash on bespoke processes for each new patient.

Summary

Julia Vitarello’s experience—from creating a single life‑saving drug for Mila to attempting a scalable biotech—highlights both the promise and the pitfalls of individualized medicine. To succeed, you need a scientific platform that can design and manufacture n‑of‑1 therapies rapidly, a regulatory strategy that anticipates uncertainty, investors who understand long‑term platform value, and a strong partnership with the patient community. EveryONE Medicines taught hard lessons; her new biotech aims to correct them. This guide provides the roadmap so that the next generation of personalized medicines can reach more than one child.